A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...

We recently compiled a list of the 10 Best Growth Stocks To Buy According To George Soros. In this article, we will look at ...

AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...

The AstraZeneca PLC ADR AZN slipped 1.58% to $77.14 Monday, on what proved to be an all-around great trading session for the ...

AstraZeneca PLC AZN shares dropped 1.66% to £115.84 Monday, on what proved to be an all-around great trading session for the ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second quarter 2024 ...

AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically ...

J.P. Morgan analyst James Gordon has maintained their bullish stance on AZN stock, giving a Buy rating on September 20. James Gordon has given his Buy rating due to a combination of factors ...

The experimental drug Astrazeneca used against breast cancer has proven not to work as hoped. The stock, listed in London, is ...

Let's catch up on the latest news from the stock market. From significant investments to major deals, fund raising and ...

London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that ...